Physician profile
Deborah Wilson
NPI 1225004898
$1,369.71
in general payments reported to CMS, 2019-2025
24 companies · $109 in 2025
The $109 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $80.16 · 2020: $111 · 2021: $37.97 · 2022: $441 · 2023: $150 · 2024: $440 · 2025: $109.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $698.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $202.71 | 2020-2025 | Axonics |
| Medtronic, INC. | $195.35 | 2022-2024 | Interstim |
| Abbvie INC. | $170.69 | 2019-2024 | Botox |
| Therapeuticsmd, INC. | $134.04 | 2019-2020 | |
| Axonics, INC. | $106.67 | 2023-2024 | Bulkamid, Axonics |
| Urogen Pharma, INC. | $78.93 | 2024 | |
| 180 Medical, INC. | $46.65 | 2022-2024 | Gentlecath |
| Myriad Genetic Laboratories, INC. | $42.65 | 2024 | Prolaris |
| Ambu INC. | $39.17 | 2024 | |
| Urovant Sciences INC | $37.61 | 2021-2022 | |
| Procept Biorobotics Corporation | $34.43 | 2024 | Aquabeam System |
| Allergan, INC. | $32.46 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $30.22 | 2024-2025 | |
| Pfizer INC. | $27.12 | 2020-2023 | |
| Sumitomo Pharma America, INC. | $22.21 | 2024 | Myfembree |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $21.28 | 2024 | Itind System |
| Janssen Biotech, INC. | $20.95 | 2025 | Erleada |
| Novartis Pharmaceuticals Corporation | $19.63 | 2024 | |
| Calyxo, INC. | $19.28 | 2025 | Cvac Aspiration System |
| Astellas Pharma US INC | $19.26 | 2025 | Xtandi |
| Mycovia Pharmaceuticals, INC. | $18.64 | 2023 | Vivjoa |
| Otsuka America Pharmaceutical, INC. | $17.28 | 2022 | |
| Merck Sharp & Dohme LLC | $16.90 | 2022 | |
| Coloplast Corp | $15.58 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.